GC Green Cross Begins First Administration of "Hunterase ICV" in Russia

Expanding Treatment Access Through Collaboration With Local Medical Professionals

GC Green Cross announced on December 3 that its Hunter syndrome (mucopolysaccharidosis type II) treatment, "Hunterase ICV" (ingredient: idursulfase beta), has been administered for the first time in Russia.

GC Green Cross

This administration was carried out through a program by the "Krug Dobra" Foundation, which provides medical support to vulnerable children. The treatment was given to a pediatric patient in the Astrakhan region at the Russian Children's Clinical Hospital (RCCH). To strengthen treatment capabilities, RCCH also provided both practical and theoretical training to medical staff from Astrakhan.

Hunterase ICV is the world's only Hunter syndrome treatment that delivers the drug directly into the brain ventricles via a device implanted in the head. This therapy reaches the patient's cerebral blood vessels and central nervous system cells, alleviating symptoms caused by central nervous system damage, such as cognitive decline and delayed psychomotor development.

Dr. Dmitry Alexandrovich Reshchikov, a neurosurgeon at RCCH who performed the first administration, stated, "This administration will be an important turning point in the treatment of patients with severe Hunter syndrome," adding, "We expect Hunterase ICV to help improve central nervous system function."

A representative from GC Green Cross commented, "Access to innovative treatments is expanding through international cooperation," and added, "We will continue our efforts to improve the treatment environment for Hunter syndrome patients."

Meanwhile, GC Green Cross plans to work with its Russian partner, Nanolek, to further expand treatment access for patients with severe Hunter syndrome.

This content was produced with the assistance of AI translation services.